A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

  1. Lin, C.-C.
  2. Garralda, E.
  3. Schöffski, P.
  4. Hong, D.S.
  5. Siu, L.L.
  6. Martin, M.
  7. Maur, M.
  8. Hui, R.
  9. Soo, R.A.
  10. Chiu, J.
  11. Zhang, T.
  12. Ma, B.
  13. Kyi, C.
  14. Tan, D.S.W.
  15. Cassier, P.A.
  16. Sarantopoulos, J.
  17. Weickhardt, A.
  18. Carvajal, R.D.
  19. Spratlin, J.
  20. Esaki, T.
  21. Rolland, F.
  22. Akerley, W.
  23. Deschler-Baier, B.
  24. Rispoli, L.
  25. Samant, T.S.
  26. Chowdhury, N.R.
  27. Gusenleitner, D.
  28. Kwak, E.L.
  29. Askoxylakis, V.
  30. De Braud, F.
  31. Show all authors +
Journal:
OncoImmunology

ISSN: 2162-402X 2162-4011

Year of publication: 2024

Volume: 13

Issue: 1

Type: Article

DOI: 10.1080/2162402X.2023.2290787 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals